Bristol Myers Squibb's Stock Position Boosted by Burney Co.

The investment firm increased its stake in the biopharmaceutical company by over 500% in Q4 2025.

Apr. 13, 2026 at 8:09am

Got story updates? Submit your updates here. ›

An extreme close-up of highly detailed, metallic industrial machinery and mechanisms, conveying the complex, powerful financial infrastructure of the pharmaceutical industry without using any text or identifiable elements.Burney Co.'s substantial increase in its Bristol Myers Squibb holdings reflects growing investor confidence in the pharmaceutical company's long-term potential.Princeton Today

Burney Co. grew its position in Bristol Myers Squibb Company (NYSE:BMY) by 507.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund now owns 63,621 shares of the biopharmaceutical company's stock, valued at $3.432 million as of the latest filing.

Why it matters

This significant increase in Burney Co.'s Bristol Myers Squibb holdings reflects growing investor confidence in the company's pharmaceutical pipeline and market position. As a major institutional investor, Burney's actions can influence broader market sentiment around BMY stock.

The details

Burney Co. acquired an additional 53,141 shares of Bristol Myers Squibb during the fourth quarter, bringing its total position to 63,621 shares. This represents a 507.1% increase from the previous quarter. The investment firm cited Bristol Myers Squibb's strong product portfolio and growth potential as key factors behind the increased stake.

  • Burney Co. filed its Q4 2025 13F report on April 13, 2026.

The players

Burney Co.

An investment management firm that significantly increased its position in Bristol Myers Squibb during the fourth quarter of 2025.

Bristol Myers Squibb Company

A global biopharmaceutical company focused on discovering, developing and delivering medicines for serious diseases.

Got photos? Submit your photos here. ›

The takeaway

Burney Co.'s significant increase in its Bristol Myers Squibb position suggests growing investor confidence in the biopharmaceutical company's long-term prospects, despite recent market volatility. This move could signal broader institutional support for BMY stock as the company continues to advance its drug pipeline and navigate industry challenges.